QCLS:NASDAQ, Q/C Technologies Inc Com Par $0.001

QCLS stock overview

Q/C Technologies Inc Com Par $0.001 (QCLS:NASDAQ) closed at $0.321 on November 16, 2026, up 4.80% on the day. The stock trades 96.1% below its 52-week high of $8.17 and 14.6% above its 52-week low of $0.280. Over the past year, it lost 89.5%. Q/C Technologies Inc Com Par $0.001 is part of the Health Care sector.

Key figures

Price
$0.321
Day change
+4.80%
Volume
3,951,315
Average volume
4,979,190
Market cap
2M+
52-week range
$0.280 – $8.17
50-day average
$0.705
200-day average
$2.86

Price action over the past year

In 252 trading sessions since November 14, 2025, QCLS closed higher on 103 days (41%). Its best day was September 16, 2026 (+118.59%) and its worst was September 14, 2026 (-67.25%). The stock moved 10% or more in a single session 31 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

QCLS news

About Q/C Technologies Inc Com Par $0.001

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), is a clinical stage pharmaceutical company committed to extending healthy lifespan. We are focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-alpha, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Our second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.

Similar stocks

Find more stocks like QCLS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.